Allies in the Race Against Time: Navigating Alzheimer's Disease with Early Detection, Therapeutic Innovations, and Patient-Centric Care – Module One
Released On
January 26, 2024
Expires On
January 25, 2025
Media Type
Internet
Completion Time
15 minutes
Specialty
Geriatric Medicine, Neurology, Primary Care
Topic(s)
Alzheimer's
This activity is provided by Global Education Group and Iridium Continuing Education
This activity is supported by an educational grant from Eisai, Inc.
Credit Available
- Physicians — maximum of 0.25 AMA PRA Category 1 Credit(s)™
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity is designed to meet the educational needs of healthcare professionals who provide care for patients primary care clinicians including internists, family physicians, radiologists, neurologists, nurse practitioners and physician assistants.
Program Overview
Alzheimer's disease (AD) is a progressive and devastating neurodegenerative disorder that affects a significant portion of the elderly population and is increasing globally. Recent advancements in disease-modifying therapies have brought hope for slowing or preventing disease progression and improving patient outcomes. However, timely diagnosis and early intervention are crucial for maximizing the likelihood of successful treatment. Clinicians, families, and researchers need to be aware of the importance of early recognition and diagnosis of AD, as well as the latest evidence on biomarkers that aid in early diagnosis. Additionally, understanding the mechanisms of action, efficacy, and safety data for new and emerging disease-modifying therapies is essential.
Download our Clinical Resource Tool
Learning Objectives
Upon completion of this activity, participants should be able to:
- Recognize the significance of early recognition and diagnosis of Alzheimer's Disease (AD) in improving patient outcomes and quality of life
Faculty
Chuck Vega, MD
Clinical Professor of Family Medicine
University of California Irvine
Irvine, CA
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Iridium. Global is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
Physician Credit Designation Statement
Global Education Group designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Relevant Financial Relationship(s)
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
- Chuck Vega, MD
- Consulting Fee (e.g., Advisory Board): Boehringer Ingelheim
- James Galvin, MD MPH
- Consulting Fee (e.g., Advisory Board): Biogen, Cognivue, Eisai, Eli Lilly, GE Healthcare, Genentech, Roche
- Stock Option Holder: Cognivue
The following planners and managers involved in the development of this activity have no relevant financial relationships with ineligible companies to disclose.
Global
The planners and managers at Global Education Group have no relevant financial relationships to disclose.
Iridium
Iridium staff and others involved with the planning, development, and review of the content for this activity have no relevant financial relationships to disclose.
Instructions for Participation and Credit
In order to receive credit for this activity, participants must:
- Read the CME/CE information and faculty disclosures
- Participate in the online activity
- Submit the evaluation form
Certificates will be emailed to the participant.
Course Viewing Requirements
Supported Browsers
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Teblets
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Iridium do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information
For CME quesions, please contact Global at 303-395-1782 or [email protected].